title: A20 attenuates allergic airway inflammation in mice.
abstract: TNF receptor 1 can activate signaling pathways leading to the activation of NF-kappaB. A20, an NF-kappaB-inducible protein, negatively regulates these signaling pathways and acts as an anti-inflammatory mediator. Therefore, A20 is viewed as a potential therapeutic target for inflammatory disease. In this study, we examined the effect of A20 on an OVA-induced allergic airway inflammation model in mice. We used an adenovirus containing A20 cDNA (Ad-A20) that was delivered intratracheally before OVA challenge. Single administration of Ad-A20 reduced airway inflammatory cell recruitment and peribronchiolar inflammation and suppressed the production of various cytokines in bronchoalveolar fluid. In addition, Ad-A20 suppressed mucus production and prevented the development of airway hyperresponsiveness. The protective effect of Ad-A20 was mediated by the inhibition of the NF-kappaB signaling pathway. Taken together, our results suggest that the development of an immunoregulatory strategy based on A20 may have therapeutic potential for the treatment of allergic asthma.
authors: Department of Immunology, Medical School and Diabetes Research Center, Chonbuk National University, Jeonju, Jeonbuk, Republic of Korea.
authors: Nam-In
authors: NI
authors: Kang
authors: Ha-Yong
authors: HY
authors: Yoon
authors: Young-Rae
authors: YR
authors: Lee
authors: Minho
authors: M
authors: Won
authors: Myoung Ja
authors: MJ
authors: Chung
authors: Jin-Woo
authors: JW
authors: Park
authors: Gang Min
authors: GM
authors: Hur
authors: Hern-Ku
authors: HK
authors: Lee
authors: Byung-Hyun
authors: BH
authors: Park
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D016535:Bronchial Hyperreactivity / Q000188:drug therapy* / Q000473:pathology; D001992:Bronchoalveolar Lavage Fluid; D003546:Cysteine Endopeptidases / Q000008:administration & dosage / Q000235:genetics / Q000494:pharmacology*; D016207:Cytokines / Q000096:biosynthesis; D005822:Genetic Vectors / Q000008:administration & dosage; D007249:Inflammation / Q000188:drug therapy*; D047908:Intracellular Signaling Peptides and Proteins / Q000008:administration & dosage / Q000235:genetics / Q000494:pharmacology*; D051379:Mice; D016328:NF-kappa B / Q000378:metabolism; D010047:Ovalbumin / Q000008:administration & dosage / Q000276:immunology; D015398:Signal Transduction / Q000187:drug effects; D000072598:Tumor Necrosis Factor alpha-Induced Protein 3
chemical_list: D016207:Cytokines; D047908:Intracellular Signaling Peptides and Proteins; D016328:NF-kappa B; D010047:Ovalbumin; D000072598:Tumor Necrosis Factor alpha-Induced Protein 3; D003546:Cysteine Endopeptidases; C513261:Tnfaip3 protein, mouse